A recent pan-cancer TCGA analysis further identified SLC31A1 as a copper-related gene whose dysregulated expression and recurrent somatic mutations associate with prognosis and immune cell infiltration across multiple tumor types, supporting its broader potential as an oncologic biomarker and therapeutic target [232]. This evidence concerns the gene SLC31A1 and cancer.